|Articles|November 10, 2017

AJMC® in the Press, November 10, 2017

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

A news article by The American Journal of Managed Care^® was highlighted in Tuesday’s CER Daily Newsfeed from the National Pharmaceutical Council. The article, “New Framework Provides Direction for Implementing Accountable Care Reform,” described a comprehensive framework that can be used to optimize integration of accountable care by drawing cross-country comparisons in Nepal, the Netherlands, and Germany.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

AJMC® in the Press, November 10, 2017

Related Content

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Global HepB3 Coverage Reaches 81.8%, but Regional Gaps Persist

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

Gaps Persist in Interstitial Lung Disease Care

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

AJMC® in the Press, November 10, 2017

Related Content

Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women

FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch

Global HepB3 Coverage Reaches 81.8%, but Regional Gaps Persist

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

Gaps Persist in Interstitial Lung Disease Care

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial